Matthias James, Spencer Emma C, Michniewicz Mara, Bendle Thomas M, Wilson Craig, Scheppke Kenneth A, Blackmore Carina, Otis Aaron, Rivkees Scott A
Centers for Disease Control and Prevention, Atlanta, GA.
Florida Department of Health, Tallahassee, FL.
Fla Public Health Rev. 2021 Feb 25;18(1):1-10.
The SARS-CoV-2 virus responsible for severe respiratory infection associated with coronavirus disease 2019 (COVID-19) was first confirmed in Florida on March 1, 2020. Responding to the pandemic, multi-agency collaborative partnerships put in place actions integrating point-of-care antibody testing at established large-scale COVID-19 testing sites where the baseline seropositivity of COVID-19 in health care workers and first responders in Florida at the start of the pandemic was established.
Determine the seropositivity of healthcare workers and first responders at five drive thru testing sites using a rapid SARS-CoV-2 antibody test in Florida from May 6 through June 3, 2020.
The first drive-thru SARS-CoV-2 antibody test site was opened at Miami Hard Rock Stadium, May 6, 2020. Testing expanded to three additional sites on May 9, 2020: Jacksonville, Orlando, and Palm Beach. The fifth and final site, Miami Beach, began testing on May 21, 2020. Healthcare workers and first responder's self-seeking SARS-CoV-2 testing were designated for antibody testing and completed a laboratory collection form onsite for the point-of-care test. All testing was performed on whole blood specimens (obtained by venipuncture) using the Cellex Inc. qSARS-CoV-2 IgG/IgM Rapid Test. Seropositivity was assessed by univariate analysis and by logistic regression including the covariates age, sex, race/ethnicity, and testing location.
As of June 3, 2020, of 5,779 healthcare workers and first responders tested, 4.1% were seropositive (range 2.6-8.2%). SARS-COV-2 antibody tests had higher odds of being positive for persons testing at the Miami Hard Rock Stadium (aOR 2.24 [95% C.I. 1.48-3.39]), persons of Haitian/Creole ethnicity (aOR 3.28 [95% C.I. 1.23-8.72]), Hispanic/Latino(a) ethnicity (aOR 2.17 [95% C.I. 1.50-3.13], and Black non-Hispanic persons (aOR 1.63 [95% C.I. 1.08-2.46]). SARS-COV-2 antibody prevalence among first responders and healthcare workers in five sites in Florida varied by race and ethnicity and by testing location.
导致2019冠状病毒病（COVID-19）相关严重呼吸道感染的严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）于2020年3月1日在佛罗里达州首次得到确认。为应对这一疫情，多机构合作伙伴关系采取行动，在既定的大规模COVID-19检测点整合即时护理抗体检测，确定了佛罗里达州医护人员和急救人员在疫情开始时COVID-19的基线血清阳性率。
2020年5月6日至6月3日，在佛罗里达州的五个免下车检测点，使用快速SARS-CoV-2抗体检测法确定医护人员和急救人员的血清阳性率。
2020年5月6日，第一个免下车SARS-CoV-2抗体检测点在迈阿密硬石体育场开放。2020年5月9日，检测扩展到另外三个地点：杰克逊维尔、奥兰多和棕榈滩。第五个也是最后一个检测点迈阿密海滩于2020年5月21日开始检测。医护人员和自行寻求SARS-CoV-2检测的急救人员被指定进行抗体检测，并在现场填写实验室采集表格以进行即时护理检测。所有检测均使用Cellex公司的qSARS-CoV-2 IgG/IgM快速检测法对全血标本（通过静脉穿刺获得）进行。通过单变量分析和包括年龄、性别、种族/族裔和检测地点等协变量的逻辑回归评估血清阳性率。
截至2020年6月3日，在接受检测的5779名医护人员和急救人员中，4.1%呈血清阳性（范围为2.6%-8.2%）。在迈阿密硬石体育场接受检测的人员（调整后比值比[aOR]为2.24[95%置信区间（C.I.）为1.48-3.39]）、海地/克里奥尔族裔人员（aOR为3.28[95% C.I.为1.23-8.72]）、西班牙裔/拉丁裔（a）族裔人员（aOR为2.17[95% C.I.为1.50-3.13]）以及非西班牙裔黑人（aOR为1.63[95% C.I.为1.08-2.46]）中，SARS-CoV-2抗体检测呈阳性的几率更高。佛罗里达州五个检测点的急救人员和医护人员中SARS-CoV-2抗体流行率因种族和族裔以及检测地点而异。
